GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) $ in Millions |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
oncology_asset
|
Jun. 30, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
|
| Other intangible assets | ||||
| Amortization of intangible assets | $ 864 | $ 2,400 | $ 1,700 | $ 4,800 |
| IPRD impairment charge | $ 300 | |||
| Number of oncology assets | oncology_asset | 2 | |||
| Lower Revised Cash Flow Projections for Inrebic | Inrebic | ||||
| Other intangible assets | ||||
| Impairment charge | 280 | |||
| Investigational Compound for Hematologic Diseases | Celgene | ||||
| Other intangible assets | ||||
| IPRD impairment charge | $ 590 | |||
| X | ||||||||||
- Definition Number Of Oncology Assets No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|